



Chronic Lymphocytic Leukaemia (CLL)

Guest Editor:

Prof. Dr. Livio Trentin

Hematology Unit, Department of
Medicine-DIMED, University of
Padua School of Medicine,
Padua, Italy

Deadline for manuscript
submissions:

closed (31 August 2021)

Message from the Guest Editor

Dear Colleagues,

Chronic lymphocytic leukemia is a rare cancer; however, as it has an incidence of almost 4 new cases in every 100,000 people/year, it is the most commonly occurring form of leukemia in western countries. In the last 15 years, our understanding of chronic lymphocytic leukemia has been revolutionized thanks to significant insights into the molecular biology of the disease and the interplay between neoplastic cells and the surrounding microenvironment. The identification of molecules pivotal to the survival of chronic lymphocytic leukemia cells has allowed us to develop targeted therapies (monoclonal antibodies, kinase inhibitors, BH3-mimetics, etc.) that have become the cornerstone of chronic lymphocytic leukemia treatment. Despite these advances, chronic lymphocytic leukemia remains an incurable disease and hypogammaglobulinemia, infections, and second primary malignancies still impinge upon patients' quality of life.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)